Open consultation

Pregabalin and gabapentin: proposal to schedule under the Misuse of Drugs Regulations 2001

Summary

We are seeking views on controlling the anti-convulsant drugs pregabalin and gabapentin.

This consultation closes at

Consultation description

This consultation seeks views on options whether, and how, to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 following the recommendation by the Advisory Council on the Misuse of Drugs (ACMD) that these 2 drugs should be controlled as Class C drugs under the Misuse of Drugs Act 1971 (‘the 1971 Act’) and placed in Schedule 3 to the Misuse of Drugs Regulations 2001.

The consultation is aimed at members of the public, healthcare professionals, institutions, all sectors within the supply chain including the pharmaceutical industry, wholesalers and community pharmacies in the UK.

Comments from all those with an interest in the consultation are welcome.

Please note that the email address below has been corrected. If you have sent a response to this address up to and including 8 December, please resend your response to the email address now stated.

Documents

A consultation on proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Impact assessment

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Impact assessment (signed by the Minister for Crime, Safeguarding and Vulnerability)

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Statement of the Chief Economist

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gsi.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ways to respond

or

Email to:

DrugLegislationTeam@homeoffice.gsi.gov.uk

Write to:

Drugs Legislation Team
5th Floor, Fry Building,
2 Marsham Street, London,
SW1 4DF

Published 13 November 2017
Last updated 8 December 2017 + full page history
  1. Email address corrected.
  2. First published.